Two healthcare giants, billions in cash flow, questionable investor enthusiasm, and the never-ending search for stocks that are actually cheap instead of merely disappointing.
November 13, 2026 | Stock Analysis • Value Investing • Market Commentary
There is something wonderfully absurd about the stock market. Investors will happily throw money at a company promising to revolutionize civilization with artificial intelligence, even if that company burns through cash faster than a teenager with their first credit card. Meanwhile, an established business generating billions of dollars in actual cash can sit in the financial equivalent of a clearance aisle because Wall Street has decided it isn't particularly exciting anymore.
Apparently, making money is no longer enough. You have to make money while promising to reinvent humanity, colonize Mars, or replace every employee with a computer that occasionally hallucinates.
I suppose that's progress.
This week, I found myself looking at two companies that seem to have committed the unforgivable offense of being mature businesses with complicated problems: Pfizer (PFE) and CVS Health (CVS).
Neither is particularly fashionable. Neither is likely to inspire a breathless television segment about the next technological revolution. And neither has a chief executive promising that shareholders will soon be able to upload their consciousness into a refrigerator.
What they do have is something I find considerably more interesting: earnings, cash flow, recognizable businesses, and stock prices that suggest investors are expecting a fair amount of disappointment.
Now, before anyone starts selling their furniture to buy pharmaceutical stocks, I should explain something. A stock trading at a low price-to-earnings ratio isn't automatically undervalued. Sometimes a stock is cheap because the market has made a mistake. Other times it's cheap because the company is about to spend the next five years demonstrating exactly why investors were right to avoid it.
My job, as I see it, is to figure out which situation I'm looking at before my money becomes an educational expense.
And this week, Pfizer and CVS deserve a closer examination.
The Market Has Developed a Strange Relationship With Reality
I've noticed that investors frequently confuse an exciting business with an attractive investment. They're not the same thing, although Wall Street has built an entire industry around pretending otherwise.
A wonderful company can be a terrible investment if I pay too much for it. Conversely, a boring company with modest growth can deliver respectable returns if I buy it at a sufficiently reasonable valuation.
This isn't a particularly revolutionary observation. Benjamin Graham was explaining variations of it long before anyone was discussing GPU clusters or artificial intelligence.
Yet every market cycle seems to require investors to rediscover the concept.
Right now, technology companies are receiving enormous attention because of their potential to transform entire industries. Some undoubtedly will. Others will discover that spending billions on infrastructure doesn't automatically create billions in profits.
That's not an argument against technology. It's an argument against confusing possibility with profitability.
According to the November 12 undervalued-stock research I'm examining, Morningstar identified communications and technology as particularly discounted areas of the market. But those apparent bargains were concentrated in relatively few large companies, and the investment cases weren't necessarily straightforward.
I find that distinction important.
When someone tells me an entire sector is undervalued, I want to know whether the businesses are genuinely inexpensive or whether analysts have simply attached optimistic fair-value estimates to companies whose future economics remain uncertain.
Those are two very different situations.
I'm much more interested in a company generating real cash today than one explaining how spectacular its cash flow might become in 2032, assuming absolutely everything goes according to plan.
Which brings me to Pfizer.
Pfizer: Apparently Making Billions Isn't Interesting Enough Anymore
Pfizer has experienced one of the more fascinating changes in investor sentiment I've watched.
During the pandemic, the company became a household name for reasons that had little to do with ordinary pharmaceutical investing. Its COVID-related products generated extraordinary revenue, and investors had to determine how much of that business would survive once the emergency faded.
The answer, unsurprisingly, was not all of it.
The problem is that Wall Street has spent considerable time treating Pfizer as though declining pandemic revenue automatically means the rest of the company is incapable of producing value.
That's a rather dramatic conclusion for a business with an extensive portfolio of medicines, significant research capabilities, and billions in operating cash flow.
As of November 11, Pfizer shares traded at approximately $29.45.
Management had recently raised its 2026 adjusted earnings guidance to between $2.95 and $3.05 per share.
Using the $3 midpoint, I get a forward adjusted price-to-earnings ratio of approximately 9.8.
Let that sink in.
Investors are valuing Pfizer at less than ten times its expected adjusted annual earnings.
That doesn't automatically make it a bargain, but it certainly gets my attention.
For comparison, if investors were willing to pay twelve times that same $3 earnings figure, the stock would be worth approximately $36 per share.
That's about 22% above the November 11 closing price.
Of course, twelve times earnings isn't some magical number handed down from the heavens. It's simply a reasonable valuation scenario that illustrates what might happen if investors become slightly less pessimistic.
The critical question is whether Pfizer can sustain those earnings.
Because if it can't, even nine times earnings might prove expensive.
Pfizer's Cash Flow Is More Interesting Than Its Reputation
One of my favorite things about financial statements is that they have an annoying habit of interfering with popular narratives.
A company can be described as struggling, disappointing, or hopelessly outdated, but eventually I want to know how much money is actually moving through the business.
During the first nine months of 2026, Pfizer generated approximately $8.83 billion in operating cash flow.
During the comparable period a year earlier, it generated approximately $6.36 billion.
That's a substantial improvement.
After approximately $1.54 billion in capital expenditures, Pfizer produced around $7.28 billion in free cash flow during those nine months.
Now we're talking.
Free cash flow matters because it's the money remaining after a business pays for the capital investments required to operate and maintain itself. It's what can potentially support dividends, reduce debt, finance acquisitions, or eventually return capital to shareholders.
It is not a guarantee that management will use the money intelligently, of course. Corporate executives have demonstrated remarkable creativity when it comes to turning shareholder cash into overpriced acquisitions.
But I would rather see a company generating billions in free cash flow than one explaining why cash flow is an outdated accounting concept.
Pfizer also offers an annualized dividend yield of approximately 5.8%, based on its $0.43 quarterly dividend and the November 11 share price.
That's an attractive income figure.
However, I don't evaluate dividends by staring lovingly at the yield and imagining quarterly deposits.
A high dividend yield can indicate an opportunity. It can also indicate that investors expect the dividend to become difficult to sustain.
The real question is whether the company can continue funding that payment while investing in new medicines and addressing its debt.
And that brings us to the part of Pfizer's investment story that deserves considerably less enthusiasm.
The Patent Cliff: When Your Best Products Stop Being Exclusively Yours
Pharmaceutical companies have an unusual business model.
They can spend enormous sums developing a successful medicine, enjoy years of attractive profits, and then watch competing manufacturers enter the market when patent protections expire.
Imagine building a successful restaurant, developing a secret recipe, and eventually being legally required to let everyone else sell essentially the same dish.
That's a simplified comparison, but it captures the economic problem.
Pfizer faces significant patent expirations over the coming years. Several important medicines will encounter generic or biosimilar competition, threatening revenue that investors have historically treated as relatively dependable.
This is not a minor inconvenience.
It's central to the investment thesis.
A pharmaceutical company trading at ten times earnings might look inexpensive until those earnings decline by 30% because its most profitable products lose exclusivity.
Suddenly, the bargain isn't quite as impressive.
Pfizer must develop, acquire, or commercialize enough successful newer medicines to replace revenue lost from older products.
Its oncology portfolio provides reasons for optimism, and the company reported 7% non-COVID revenue growth in the third quarter.
But optimism is not the same thing as certainty.
Drug development is expensive, unpredictable, and occasionally spectacularly disappointing.
A promising clinical program can absorb years of investment before producing results that make shareholders wish management had simply purchased Treasury securities.
Pfizer also carries approximately $62.7 billion in debt.
That's a serious financial obligation, even for a large pharmaceutical company.
I don't consider Pfizer financially distressed based on the figures in this report, but I also refuse to pretend that substantial debt disappears because a company has a recognizable name.
Debt has to be serviced. Eventually, it has to be refinanced or repaid. And every dollar committed to financial obligations is a dollar that cannot simultaneously fund another research project, acquisition, or shareholder distribution.
This is why I consider Pfizer a legitimate value candidate rather than an obvious bargain.
There is a difference.
The opportunity exists because investors are worried about real problems. My responsibility is to determine whether the market has exaggerated those problems.
CVS Health: A Company That Apparently Needs to Recover Twice
CVS Health presents an entirely different investment puzzle.
Most people recognize CVS as a pharmacy retailer. But the business extends far beyond selling prescriptions, shampoo, and the occasional emergency birthday card.
Through its insurance, pharmacy services, and healthcare operations, CVS participates in several interconnected parts of the American healthcare system.
That creates opportunities for scale and coordination.
It also creates an impressive collection of ways for something to go wrong.
Medical costs rise. Insurance reimbursements change. Government programs adjust payment structures. Acquisitions fail to produce expected benefits. Regulators decide that yesterday's perfectly acceptable business arrangement deserves another examination.
Healthcare is complicated enough without attempting to operate several major pieces of it simultaneously.
And CVS has been learning that lesson in public.
Still, its latest financial results suggest the business may be making progress.
At the November 11 closing price of approximately $89.52, CVS traded at roughly 10.9 times management's minimum 2026 adjusted earnings forecast of $8.20 per share.
That's not an outrageous valuation for a company generating substantial revenue and showing improving operating results.
In the third quarter, CVS reported revenue of approximately $108.4 billion, representing 5.4% growth.
Adjusted earnings per share increased from $1.60 to $2.09.
Adjusted operating income rose from approximately $3.46 billion to $4.19 billion.
Those aren't insignificant improvements.
Management also raised its full-year adjusted EPS outlook to at least $8.20 and operating cash-flow guidance to at least $15.5 billion.
If I were looking only at the income statement, I might be tempted to declare that the turnaround is working.
Unfortunately, investing requires more than identifying a company whose quarterly numbers look better than the previous quarter's.
It also requires paying attention to the stock price.
And CVS investors have already noticed the improvement.
The Bargain That Started Disappearing While Everyone Was Looking at It
Here's where the CVS story becomes particularly interesting.
Following its November 4 earnings announcement, CVS shares traded around $79.96.
By November 11, they had climbed to approximately $89.52.
That's a gain of roughly 12% in a week.
Apparently, investors discovered that a company reporting better earnings might actually be worth more money.
Groundbreaking stuff.
But that rebound creates a problem for anyone considering buying shares today.
At $79.96, the valuation offered considerably more room for disappointment. At $89.52, investors are paying a higher price for essentially the same recently reported financial information.
The business may be improving, but the investment opportunity has become less generous.
I cannot emphasize this enough: a better company is not automatically a better investment after its stock price rises.
Price matters.
If I apply a hypothetical thirteen-times earnings multiple to CVS's $8.20 adjusted EPS forecast, I arrive at approximately $106.60 per share.
That represents roughly 19% potential appreciation from the November 11 closing price.
Not terrible.
But that scenario assumes CVS can sustain its earnings recovery and persuade investors that those earnings deserve a higher multiple.
Neither outcome is guaranteed.
The stock's rapid rebound tells me that some of the easy optimism may already be reflected in the price.
And I have no interest in congratulating myself for discovering a turnaround after everyone else has spent the previous week bidding up the shares.
CVS Has a Medical-Cost Problem That Won't Disappear Because Investors Feel Better
The biggest concern surrounding CVS is not whether Americans will continue needing healthcare.
They will.
The concern is how much providing that healthcare will cost and whether CVS can price its insurance products profitably.
Medical-cost inflation has placed considerable pressure on health insurers, particularly in Medicare Advantage.
When patients use more medical services than expected, insurers can find themselves paying substantially more in claims than their pricing assumptions anticipated.
That can quickly damage profitability.
And unlike a manufacturer that might offset higher raw-material costs by adjusting production, an insurer cannot simply tell its policyholders that medical procedures have become inconveniently expensive and should therefore be postponed until the next earnings quarter.
CVS must manage these pressures through pricing, underwriting, benefit design, operating efficiency, and careful forecasting.
The company also needs to demonstrate that its acquisitions are producing genuine economic benefits.
I have always been suspicious of corporate strategies that promise to create value primarily by becoming enormous.
Size can provide advantages, but it also creates complexity. And complexity has a habit of producing expenses that somehow never appeared in the original investor presentation.
Another important distinction is cash flow.
CVS's operating cash-flow guidance of at least $15.5 billion sounds impressive, and it is a substantial amount.
But operating cash flow is not the same as free cash flow.
Capital expenditures still matter. So do debt obligations, acquisitions, and the cash requirements of operating a complicated healthcare organization.
I want to know how much money is actually available after the business funds its necessary investments.
Until that becomes clearer, I consider CVS an improving company rather than a guaranteed bargain.
Berkshire Hathaway: Even Great Businesses Can Become Less Attractive
While examining Pfizer and CVS, I also considered Berkshire Hathaway.
Berkshire is a fascinating example of why I refuse to evaluate investments based solely on business quality.
The company possesses enormous financial resources, diversified operations, and a long history of disciplined capital allocation.
Its reported $9.6 billion in third-quarter share repurchases also provides evidence that management considered buying its own stock an attractive use of capital.
I pay attention when a company with substantial financial flexibility chooses to repurchase shares.
But I also pay attention to what happens afterward.
Berkshire's Class B shares rose from approximately $542.49 on October 30 to $588.24 on November 11.
That's a significant move in a relatively short period.
Did Berkshire suddenly become a dramatically better business?
Probably not.
Did the price investors were being asked to pay become considerably less attractive?
Absolutely.
This is where patience becomes an actual investment skill rather than something people mention in inspirational quotations.
I can admire Berkshire without buying it at every price.
I can believe management is competent without assuming every share purchase represents an extraordinary opportunity.
And I can wait.
Wall Street doesn't particularly enjoy waiting because waiting doesn't generate much trading activity.
Fortunately, I'm not obligated to keep a brokerage firm's commission department entertained.
Oracle, CoreWeave, and the Difference Between Growth and Financial Strength
The broader market provides an interesting contrast to these healthcare opportunities.
Consider Oracle and CoreWeave, two businesses associated with the enormous expansion of artificial intelligence infrastructure.
Both participate in areas with substantial potential demand.
But potential demand is not the same as financial resilience.
Oracle faces heavy infrastructure spending and financing requirements as it expands its AI-related capabilities. Even if demand remains strong, the timing and magnitude of future free cash flow are important uncertainties.
CoreWeave presents an even more aggressive financial profile.
The November 12 research report identified approximately $46.9 billion in debt alongside continuing losses.
That's an extraordinary amount of financial obligation for a business whose investment case depends heavily on future growth.
Now, I'm not suggesting that either company is doomed.
Technology infrastructure can be expensive to build, and businesses sometimes accept substantial financial burdens because they expect future revenue to justify the investment.
But there's a difference between accepting calculated risk and pretending that debt is irrelevant because the company has an exciting presentation.
If I have to make heroic assumptions about future profitability merely to justify today's valuation, I become uncomfortable.
I prefer investments where the business already generates enough cash to support a meaningful portion of the valuation.
That doesn't eliminate risk.
It simply reduces my dependence on everything going perfectly.
What I Actually Want From an Undervalued Stock
Over the years, I've become increasingly convinced that successful value investing involves rejecting more opportunities than accepting them.
A low P/E ratio isn't enough.
A high dividend yield isn't enough.
A stock trading 40% below its previous high certainly isn't enough.
The market doesn't owe investors a return to yesterday's price simply because yesterday's price was higher.
What I want is a business with durable earning power, a balance sheet that can survive unfavorable conditions, management that allocates capital sensibly, and a valuation that doesn't require extraordinary optimism.
I also want an identifiable reason the market might eventually reconsider its opinion.
That last requirement matters.
A stock can remain undervalued for years if nothing happens to change investor expectations.
Pfizer has several potential catalysts: newer medicines replacing older products, successful drug development, improving free cash flow, and debt reduction.
CVS has its own: improving insurance profitability, stabilizing medical-cost trends, better cash conversion, and a credible outlook for 2027.
Those are developments I can monitor.
They are more useful than hoping investors wake up one morning and collectively decide to become cheerful.
I also want a margin of safety.
That phrase gets thrown around so casually that it sometimes seems to mean nothing more than buying a stock after it has declined.
To me, a margin of safety means purchasing a business at a price sufficiently below a conservative estimate of its value that reasonable disappointments don't destroy the investment thesis.
It's protection against being wrong.
And since I have no intention of pretending that my forecasts are infallible, I consider that protection essential.
My Verdict: Pfizer Gets My Attention, CVS Gets My Patience
After examining the numbers, Pfizer is the company I would investigate first.
At approximately 9.8 times expected adjusted earnings, with improving operating cash flow and a substantial dividend, the valuation provides a credible starting point.
But I would not buy it simply because the multiple is low.
I would want a detailed examination of its patent-expiration schedule, expected revenue losses, replacement products, normalized free cash flow, and debt repayment capacity.
If those factors suggest Pfizer can sustain something close to its current earning power, the stock could offer an attractive combination of income and capital appreciation.
If they don't, the low multiple may be entirely justified.
CVS requires a different approach.
I like the improvement in operating performance. I like the stronger adjusted earnings. And I appreciate that management has raised its outlook.
What I don't particularly like is paying 12% more than investors were paying a week earlier without a corresponding change in the underlying financial results.
That doesn't make CVS unattractive.
It makes patience more valuable.
I would prefer either a more attractive entry price or additional evidence that the company's earnings recovery can continue into 2027.
Berkshire remains worth monitoring, but its recent appreciation has reduced the immediate appeal.
And the more speculative AI infrastructure businesses can continue promising extraordinary futures while I examine companies that already produce meaningful cash.
I'm comfortable with that arrangement.
The Bottom Line: Boring Might Be the Most Underrated Investment Strategy
There's a strange pressure in modern investing to always be doing something.
Buy the breakout. Chase the momentum. Rotate into the next sector. Find the next ten-bagger. React to every earnings report as though the fate of civilization depends on the next thirty minutes of trading.
It's exhausting.
And I suspect it makes plenty of people poorer.
I've come to appreciate that some of the most interesting investment opportunities begin with a relatively unexciting observation: a profitable company is trading at a price that may underestimate its long-term earning power.
That's it.
No revolutionary technology required. No elaborate prediction about the future of humanity. No need to explain why traditional financial metrics have supposedly become obsolete.
Just a business, its financial statements, and a price.
Pfizer and CVS are not perfect companies. Their problems are substantial, and investors have legitimate reasons to be cautious.
But that's precisely why they're worth examining.
If everyone loved them, their shares would probably be more expensive.
The opportunity in value investing often exists because something has gone wrong, investors have become uncomfortable, or the market has decided that a company's problems are more important than its strengths.
Sometimes the market is right.
Sometimes it isn't.
My goal isn't to prove Wall Street wrong simply for the satisfaction of doing so. My goal is to identify situations where the price offers sufficient compensation for the risks I'm accepting.
Right now, Pfizer looks like the more compelling research candidate. CVS looks like a turnaround worth monitoring, preferably without chasing its recent rally.
Neither requires me to predict the next technological revolution.
And frankly, after watching investors enthusiastically finance businesses that may not produce meaningful free cash flow for years, I find the prospect of analyzing companies that already generate billions rather refreshing.
Maybe I'm old-fashioned.
Maybe I just prefer owning businesses that can pay their bills without constantly explaining why their financial difficulties are actually evidence of extraordinary growth.
Either way, I'll keep looking through the market's bargain bin.
Because every once in a while, beneath the abandoned growth stories, disappointed expectations, and companies Wall Street has decided are no longer fashionable, there's something genuinely valuable.
The trick is knowing the difference between a bargain and a problem wearing a discount sticker.
And I have absolutely no intention of paying full price for either.
Disclaimer: This article reflects my interpretation of the supplied November 12, 2026 undervalued-stock research, using November 11 closing prices and the financial figures reported there. Valuation examples are hypothetical, adjusted earnings differ from GAAP earnings, and future performance is uncertain. This article is for informational purposes and is not personalized investment advice.
Comments
Post a Comment